Essential thrombocytosis: Difference between revisions
No edit summary |
No edit summary |
||
| Line 30: | Line 30: | ||
==Treatment== | ==Treatment== | ||
[[Essential thrombocytosis medical therapy#Medical therapy|Medical Therapy]] | [[Essential thrombocytosis surgery|Surgery]] | [[Essential thrombocytosis primary prevention|Primary Prevention]] | [[Essential thrombocytosis secondary prevention|Secondary Prevention]] | [[Essential thrombocytosis medical therapy#Medical therapy|Medical Therapy]] | [[Essential thrombocytosis surgery|Surgery]] | [[Essential thrombocytosis primary prevention|Primary Prevention]] | [[Essential thrombocytosis secondary prevention|Secondary Prevention]] | [[Essential thrombocytosis cost-effectiveness of therapy|Cost-Effectiveness of Therapy]] | [[Essential thrombocytosis future or investigational therapies|Future or Investigational Therapies]] | ||
==Resources== | ==Resources== | ||
Revision as of 13:23, 16 November 2015
For patient information click here
|
Essential thrombocytosis Microchapters |
|
Differentiating Essential thrombocytosis from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Essential thrombocytosis On the Web |
|
American Roentgen Ray Society Images of Essential thrombocytosis |
|
Risk calculators and risk factors for Essential thrombocytosis |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Soujanya Thummathati, MBBS [2]
Synonyms and keywords: Essential thrombocythemia, primary thrombocythemia, inherited essential thrombocythemia, inherited Essential thrombocytosis, inherited essential thrombocythemia, inherited ET, congenital essential thrombocytosis, congenital essential thrombocythaemia, congenital essential thrombocythemia, congenital ET, hereditary essential thrombocytosis, hereditary essential thrombocythaemia, hereditary essential thrombocythemia, hereditary ET, familial essential thrombocythemia, familial essential thrombocytosis, familial essential thrombocythaemia, familial ET, Epstein-Goedel syndrome, Hemorrhagic thrombocytosis, Hemorrhagic thrombocythemia, Haemorrhagic thrombocytosis, Haemorrhagic thrombocythemia, ET
Overview
Historical Perspective
Classification
Pathophysiology
Epidemiology and Demographics
Risk Factors
Screening
Causes
Differentiating Essential thrombocytosis from other Diseases
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Criteria | History & Symptoms | Physical Examination | Laboratory Findings | Electrocardiogram | Chest X Ray | CT | MRI | Echocardiography or Ultrasound | Other Imaging Findings | Other Diagnostic Studies
Treatment
Medical Therapy | Surgery | Primary Prevention | Secondary Prevention | Cost-Effectiveness of Therapy | Future or Investigational Therapies
Resources
- Cancerbackup Essential Thrombocytosis page
- CMPD Education Foundation
- MPD Foundation and Research Alliance - Register for a free newsletter
- Overview of Agrylin, the tradename for anagrelide hydrochloride